(ADCT) ADC Therapeutics - Overview
Stock: Antibody Conjugates, Zynlonta, CD19, Lymphoma, Pipeline
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 91.3% |
| Relative Tail Risk | -10.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.40 |
| Alpha | 109.41 |
| Character TTM | |
|---|---|
| Beta | 1.469 |
| Beta Downside | 1.080 |
| Drawdowns 3y | |
|---|---|
| Max DD | 89.46% |
| CAGR/Max DD | -0.03 |
Description: ADCT ADC Therapeutics January 01, 2026
ADC Therapeutics SA (NYSE:ADCT) is a Swiss biotech that has built an antibody-drug conjugate (ADC) platform aimed at delivering cytotoxic payloads directly to cancer cells, focusing on both hematologic malignancies and solid tumors.
Its lead product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed ADC that has earned accelerated U.S. FDA approval, conditional EU approval, and conditional Chinese NMPA approval for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after ≥ 2 prior lines of therapy.
ADCT is pursuing broader indications for ZYNLONTA, including earlier-line DLBCL, follicular lymphoma (FL) and marginal-zone lymphoma (MZL), via the confirmatory LOTIS-5 Phase 3 trial, the LOTIS-7 Phase 1b combination study, and multiple investigator-initiated trials (IITs). The pipeline also contains a CD22-targeted ADC (ADCT-602) in a Phase 1/2 IIT for refractory B-cell ALL and pre-clinical ADC candidates against Claudin-6, NaPi2b, PSMA, and ASCT2.
Key market metrics: the global ADC market is projected to grow at a CAGR of ~ 12 % through 2030, driven by higher oncology spending (U.S. oncology drug sales > $120 bn in 2023) and regulatory incentives for targeted therapies. ADCT’s cash runway exceeded $150 million at year-end 2023, and ZYNLONTA generated ~$45 million in Q4 2023 sales, reflecting early commercial traction in a niche but expanding CD19-ADC space.
For a deeper, data-driven assessment of ADCT’s valuation assumptions and scenario analysis, you may find the ValueRay platform worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -166.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.46 > 0.02 and ΔFCF/TA -7.05 > 1.0 |
| NWC/Revenue: 299.3% < 20% (prev 375.2%; Δ -75.89% < -1%) |
| CFO/TA -0.46 > 3% & CFO -131.9m > Net Income -166.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.63 > 1.5 & < 3 |
| Outstanding Shares: last quarter (136.4m) vs 12m ago 30.17% < -2% |
| Gross Margin: 92.73% > 18% (prev -0.83%; Δ 9356 % > 0.5%) |
| Asset Turnover: 23.55% > 50% (prev 20.26%; Δ 3.29% > 0%) |
| Interest Coverage Ratio: -2.30 > 6 (EBITDA TTM -113.5m / Interest Expense TTM 50.5m) |
Altman Z'' -15.00
| A: 0.78 (Total Current Assets 287.1m - Total Current Liabilities 62.0m) / Total Assets 289.8m |
| B: -5.62 (Retained Earnings -1.63b / Total Assets 289.8m) |
| C: -0.36 (EBIT TTM -116.1m / Avg Total Assets 319.4m) |
| D: -3.07 (Book Value of Equity -1.62b / Total Liabilities 527.9m) |
| Altman-Z'' Score: -18.90 = D |
Beneish M -3.04
| DSRI: 0.90 (Receivables 22.9m/24.0m, Revenue 75.2m/70.7m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.26 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: 1.06 (Revenue 75.2m / 70.7m) |
| TATA: -0.12 (NI -166.9m - CFO -131.9m) / TA 289.8m) |
| Beneish M-Score: -3.04 (Cap -4..+1) = AA |
What is the price of ADCT shares?
Over the past week, the price has changed by +11.08%, over one month by +13.28%, over three months by -3.61% and over the past year by +147.53%.
Is ADCT a buy, sell or hold?
- StrongBuy: 4
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ADCT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8 | 99.5% |
| Analysts Target Price | 8 | 99.5% |
| ValueRay Target Price | 4.3 | 6.7% |
ADCT Fundamental Data Overview February 03, 2026
P/B = 2.5787
Revenue TTM = 75.2m USD
EBIT TTM = -116.1m USD
EBITDA TTM = -113.5m USD
Long Term Debt = 115.2m USD (from longTermDebt, last quarter)
Short Term Debt = 933.0k USD (from shortTermDebt, last quarter)
Debt = 117.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -117.5m USD (from netDebt column, last quarter)
Enterprise Value = 329.7m USD (447.2m + Debt 117.3m - CCE 234.7m)
Interest Coverage Ratio = -2.30 (Ebit TTM -116.1m / Interest Expense TTM 50.5m)
EV/FCF = -2.49x (Enterprise Value 329.7m / FCF TTM -132.3m)
FCF Yield = -40.11% (FCF TTM -132.3m / Enterprise Value 329.7m)
FCF Margin = -175.9% (FCF TTM -132.3m / Revenue TTM 75.2m)
Net Margin = -222.0% (Net Income TTM -166.9m / Revenue TTM 75.2m)
Gross Margin = 92.73% ((Revenue TTM 75.2m - Cost of Revenue TTM 5.47m) / Revenue TTM)
Gross Margin QoQ = 92.68% (prev none%)
Tobins Q-Ratio = 1.14 (Enterprise Value 329.7m / Total Assets 289.8m)
Interest Expense / Debt = 11.42% (Interest Expense 13.4m / Debt 117.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -91.7m (EBIT -116.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.63 (Total Current Assets 287.1m / Total Current Liabilities 62.0m)
Debt / Equity = -0.49 (negative equity) (Debt 117.3m / totalStockholderEquity, last quarter -238.2m)
Debt / EBITDA = 1.03 (negative EBITDA) (Net Debt -117.5m / EBITDA -113.5m)
Debt / FCF = 0.89 (negative FCF - burning cash) (Net Debt -117.5m / FCF TTM -132.3m)
Total Stockholder Equity = -219.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -52.26% (Net Income -166.9m / Total Assets 289.8m)
RoE = 76.04% (negative equity) (Net Income TTM -166.9m / Total Stockholder Equity -219.6m)
RoCE = 111.2% (negative capital employed) (EBIT -116.1m / Capital Employed (Equity -219.6m + L.T.Debt 115.2m))
RoIC = 87.11% (negative operating profit) (NOPAT -91.7m / Invested Capital -105.3m)
WACC = 10.85% (E(447.2m)/V(564.5m) * Re(11.33%) + D(117.3m)/V(564.5m) * Rd(11.42%) * (1-Tc(0.21)))
Discount Rate = 11.33% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 28.77%
Fair Price DCF = unknown (Cash Flow -132.3m)
EPS Correlation: 55.49 | EPS CAGR: 6.33% | SUE: 1.29 | # QB: 1
Revenue Correlation: -42.78 | Revenue CAGR: -0.93% | SUE: -0.16 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.27 | Chg30d=+0.010 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=-1.07 | Chg30d=+0.035 | Revisions Net=+1 | Growth EPS=+22.8% | Growth Revenue=+1.1%